Celera Diagnostics Begins to Find its Place Within Applera | GenomeWeb

NEW YORK, July 24 – As part of Applera’s $75 million program to transform itself into a drug discovery and diagnostics powerhouse, company executives for the first time Tuesday discussed in detail how Celera Diagnostics, the newest member of the Applera family, would distinguish itself from its more well-known brethren, Celera Genomics and Applied Biosystems (ABI).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.